We report the case of a 51-year-old patient with metastatic prostate cancer at diagnosis and primary refractoriness to both androgen ablation therapy and docetaxel.
At the time of cabazitaxel initiation, the patient had only osseous metastases and was constrained to a wheelchair because of bone pain. Ten cycles of cabazitaxel were administered, and a remarkable response was achieved, with improvement in biochemical markers, performance status, and bone scan findings. Two months after suspension of treatment by choice, the patient developed jaundice because of massive hepatic metastases and died after a few days because of hepatic failure.
Written by:
Di Lorenzo G, Buonerba C, de Placido S. Are you the author?
Genitourinary Cancer Section, Medical Oncology, University Federico II, Naples, Italy.
Reference: Anticancer Drugs. 2014 Oct 21. Epub ahead of print.
doi: 10.1097/CAD.0000000000000180
PubMed Abstract
PMID: 25340916